



Intelligent Life Science

Media Contacts:

Evaluate and EP Vantage (for general questions)

Christine Lindgren

+1 617-866-3906

christine.lindgren@evaluategroup.com

Instinctif Partners (for non-U.S. media)

Gemma Harris/Melanie Toyne Sewell

+44 (0) 20 7457 2020

evaluate@instinctif.com

Jani Communications (for U.S. media)

Janice Foley

+1-617-823-5555

janifoley@verizon.net

Edelman Japan KK (for Japanese media)

Yamada/Masaki

TEL: [+81\(3\)-4360-9000](tel:+81(3)-4360-9000)

Email: EvaluateJapanPR@edelman.com

Worldwide Medtech Sales Forecast to Reach \$522 Billion by 2022 with a CAGR of 5.1% between 2016 and 2022

EvaluateMedTech Report Launches in Conjunction with The MedTech Conference

LONDON, BOSTON, TOKYO, SAN FRANCISCO (September 25th, 2017) — The

“[EvaluateMedTech World Preview 2017. Outlook to 2022](#)” report from life science

commercial intelligence firm Evaluate Ltd, reveals Medtronic was the leading medtech company in 2016 with sales of almost \$30bn and will retain the crown in 2022 with sales forecast to reach \$37.7bn; Abbott to jump to 3rd place as its acquisition of St. Jude creates the world’s second largest cardiology company.

“After a slow year in 2016 as companies that had made large buys the year before paused to digest their purchases, M&A activity is once again on the up. At nearly \$50bn, the total value of mergers closed in the first half of 2017 has already eclipsed the total for all of 2016”, said

Elizabeth Cairns, report author. “Despite this the number of deals struck has been falling; mergers are getting bigger, but also scarcer”, she added.

“EvaluateMedTech World Preview 2017, Outlook to 2022 - Analysis Highlights:

- Total value of medtech M&A deals rises by a massive 178% in H1 2017
- In vitro diagnostics is expected to remain the largest medtech segment in 2022 with annual sales of \$70bn; Roche remains top player with expected sales of \$12.8bn in 2022
- Total value of medtech venture financing deals rises 56% in H1 2017 despite the number of deals falling by 11%
- Total value of medtech IPOs continues to fall in H1 2017 to \$122m
- Global medtech R&D spend set to grow by 3.7% (CAGR) to \$33.5bn by 2022
- Following the 10 year high in 2015, number of first-time PMAs and HDEs down 22% in 2016

The analysis is based on in-depth consensus forecast models for the top 300 global medtech companies available within the EvaluateMedTech service. The report can be downloaded at www.evaluategroup.com/MedtechWorldPreview2017. Copies of the report executive summary will be available at Evaluate’s booth #806 during The MedTech Conference this week in San Jose, CA.

###

About Evaluate

Evaluate is the trusted provider of commercial intelligence including product sales and consensus forecasts to 2022 for commercial teams and their advisors within the global life science industry. We help our clients make high value decisions through superior quality, timely, must-have data and insights, combined with personalised, expert client support. Our online subscription services cover the pharmaceutical, biotech and medtech sectors. Our Custom Services group delivers project based analytical and data services. EP Vantage, our independent, award-winning editorial team, offers data-driven, forward-looking news, commentary and analysis on a daily basis. For more information, please visit: www.evaluategroup.com. On Twitter:

[@evaluatepharma](#), [@evaluatemedtech](#), [@evaluateJP](#), [@epvantage](#). On Instagram:
[EvaluateLtd](#).